SCHEMBL4516764

SCHEMBL4516764

O=C1C(Cc2ccc(NCc3ccccc3)cc2Cl)CCN1C1CCCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.60
BRD4 O60885 1/20 0.40
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAOA P21397 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
PDE9A O76083 1/20 0.35
P2RX7 Q99572 2/20 0.35
FPR2 P25090 1/20 0.35
TSHR P16473 1/20 0.35
PREP P48147 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000838 0.87 HSD11B1 (0.57) HSD11B1LMNASMN1; SMN2P2RX7
SCHEMBL4501753 0.85 HSD11B1 (0.48) HSD11B1LMNASMN1; SMN2OPRM1OPRK1
Hydrochloric Acid SCHEMBL4525353 0.84 HSD11B1 (0.47) HSD11B1LMNASMN1; SMN2OPRM1OPRK1
SCHEMBL2995925 0.83 HSD11B1 (0.65) HSD11B1LMNASMN1; SMN2TDP1
SCHEMBL4514220 0.83 HSD11B1 (0.51) HSD11B1LMNAHTTSMN1; SMN2P2RX7
SCHEMBL4511944 0.82 HSD11B1 (0.52) HSD11B1SMN1; SMN2ACHE
SCHEMBL4511217 0.82 HSD11B1 (0.52) HSD11B1BRD4LMNAHTTDDB1
SCHEMBL3554331 0.81 HSD11B1 (0.60) HSD11B1
SCHEMBL4515800 0.81 HSD11B1 (0.51) HSD11B1HTTSMN1; SMN2OPRM1OPRD1
SCHEMBL4519338 0.80 HSD11B1 (0.60) HSD11B1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885BRD4 3776/4885LMNA 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.